
|Articles|January 22, 2004
Prostate cancer immunotherapy extends survival, study shows
Patients with Gleason scores =7 receiving an investigational form of immunotherapy for prostate cancer showed a significant survival advantage.
Advertisement
Newsletter
Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
Theranostic therapies expand frontline use in prostate cancer
2
FDA removes warning labels on hormone replacement therapy
3
BioProtect Balloon Spacer shows sustained quality-of-life benefits in long-term study
4
Jonathan Henderson, MD, outlines key lessons in urology practice management
5




















